Delivery Order SPE2DB24D9113-SPE2DB25FEQDL
Award Date 9/10/25
Potential Completion Date 10/1/25
Potential Value $6.2K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order valued at $1,547.40 for XOLAIR 75 mg/0.5 ml syringes. The award, issued on September 11, 2025, with an ultimate completion date of October 2, 2025, represents a firm fixed-price delivery order with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order for XOLAIR 150 MG/ML syringes valued at $3,094.80. The contract, which was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, carries firm fixed-price terms and does not utilize a set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $11,605.50 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, and the contract carries no set-aside designation. The delivery order is scheduled for completion by September 24, 2025, and represents a single purchase under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,094.80 by the Defense Logistics Agency on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,547.40 to DMS Pharmaceutical Group Inc. for the supply of XOLAIR 150 mg/ml syringes. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, operates under a firm fixed-price arrangement with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 150 mg/ml Xolair syringes. This $1,547.40 firm fixed-price delivery order was awarded on September 2, 2025, with an ultimate completion date of September 23, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on the open market despite its small business status. Xolair...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,712.22 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml auto-injector on August 13, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price delivery order was issued under the SPE2DB Indefinite Delivery Contract (IDC), a $500 million single-award vehicle that enables DLA to procure pharmaceutical products and medical supplies for Department of Defense healthcare facilities worldwide. The...
- The Defense Logistics Agency issued a delivery order to DMS Pharmaceutical Group Inc. on September 11, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $3,094.80. This firm fixed-price delivery order is scheduled for ultimate completion by October 2, 2025, and represents no set-aside designation. XOLAIR (omalizumab) is a monoclonal antibody used to treat moderate to severe allergic asthma and chronic idiopathic urticaria, indicating this delivery supports...
- The U.S. Defense Logistics Agency (DLA) awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a firm fixed-price delivery order valued at $8,561.10 for XOLAIR 150 mg/ml. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion single-award vehicle valid through November 2026. The award carries no set-aside designation...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes valued at $12,379.20. This firm fixed-price delivery order, issued on September 9, 2025, is expected to be completed by September 30, 2025, and operates under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at approximately $500 million through...